Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:09 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020489
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Other liabilities | 3,964 | (10,256) |
| Net cash provided by operating activities | 127,044 | 103,549 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (34) | (142) |
| Net cash used in investing activities | (34) | (142) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options and employee stock purchase plan | 216 | 11,013 |
| Taxes paid related to net share settlement of share-based awards | — | (737) |
Item 16. Form 10-K Summary
FAQ
- What is Ironwood Pharmaceuticals's capex?
- Ironwood Pharmaceuticals (IRWD) reported capex of $0 in Q4 2025.
- What is the long-term trend for Ironwood Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's capex has grown at a -42.8% compound annual growth rate (CAGR), from $326.75K to $35K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Ironwood Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude